SecBot SecBot

NGEN

NERVGEN PHARMA CORP.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001751912 Biotech & Drug Discovery
$1.40 −0.03 (−2.10%)
Oct 26 4:00 PM ET · prev $1.43
Market cap
$152.8M
Micro cap
Median target
$10.00
+614% · range $10.00–10.00
1 year
−48.9%
from $2.74 · Oct 27
30 days
−25.5%
from $1.88
52-week range
$1.40–5.97
at the low
Avg volume 20D
479.4K
Oct 14 spike 1.30M
Short interest
5.83M
≈5.5% of shares · +6.2%
Days to cover
11.3
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 1 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/5
Strongest BEARISH NervGen Pharma announced it will restate financial statements for FY2024, FY2025, and Q2 2026 due to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 0 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.077 → −$0.105 over 90 days.

  • Short sellersSTEADY

    Short interest +6.2% to 5.83M shares. 11.3 days to cover, ≈5.5% of shares.

  • TrendDOWNTREND

    27% below its 50-day average. New closing low $1.40 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPDOUBLED435,962$898.1K
UBS Group AGDOUBLED379,726$782.2K
OSAIC HOLDINGS, INC.ADD51,093$105.3K
HRT FINANCIAL LPDOUBLED43,858$90.0K
LPL Financial LLCADD26,710$55.0K
Steward Partners Investment Advisory, LLCADD6,000$12.4K
JONES FINANCIAL COMPANIES LLLPDOUBLED3,774$7.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +614%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jul 14, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 13, 2026Leerink Partners
INITIATE
INITIATEOutperform

Earnings setup

Estimates
−$0.10
EPS estimate, this quarter
−36%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.10-$0.10–-$0.10+2.8%$0.00
Next Q-$0.15-$0.15–-$0.15+2.6%$0.00
Current FY-$0.49-$0.49–-$0.49+2.0%$0.00
Next FY-$0.34-$0.40–-$0.27+0.8%$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 1, 2026
Clinical Trial
NVG-291 in Spinal Cord Injury Subjects
Phase 2 · COMPLETED
Sep 25, 2026
Restatement
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing…
Sep 9, 2026
Company news
NervGen to Host Inaugural R&D Day on September 30, 2026
VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing…
Aug 13, 2026
Earnings
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing…
Jul 31, 2026
Short interest
Short Interest: NGEN up 21% to 5.4M shares
Settlement 2026-07-31 | Days to cover: 9.83 | ≈6.62% of shares outstanding (est.)

Short side

FINRA· Sep 30, 2026
5,832,084
shares short
+6.2%
vs prior settlement
11.3
days to cover
≈5.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 SEC
NervGen Pharma announced it will restate financial statements for FY2024, FY2025, and Q2 2026 due to non-cash…
6-K — Impact 7/10
Sep 25, 2026 Press
NervGen Pharma announced a non-cash restatement of its 2025 annual and Q2 2026 interim financial statements, revising…
Impact 4/10
Sep 25, 2026 Restatement
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage
Sep 24, 2026 SEC
NervGen Pharma Corp. filed a Form 6-K announcing the resignation of KPMG Canada as its auditor and the appointment of…
6-K — Impact 3/10
Aug 13, 2026 SEC
NervGen Pharma reported Q2 2026 financial results, highlighting a net loss of C$29.2M (C$0.32/share basic) vs C$9.1M…
6-K — Impact 5/10
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — DOUBLED
435,962 shares ($898.1K)
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
379,726 shares ($782.2K)
May 21, 2026 Press
NervGen Pharma priced a $60M underwritten public offering of 24M common shares and warrants, with shares at $2.50 and…
Impact 6/10

SecBot reports

12 filings · 4 press releases · 2 bullish · 5 bearish · 5 neutral
All NGEN filing & press-release reports (16)